Evidence map›Paper›PMID 39732963›Full record

ArticleScientific reports2024

Development and validation of a prognostic model based on m6A-related lncRNAs to predict prognosis for papillary renal cell cancer patients.

Xianlu Zhang, Jiyuan Hu, Haoyuan Zheng, Jiayi Ren, Siyu Mu, Yiming Chen, Guoli Song, Ya-Ang Chen, Gejun Zhang

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xianlu Zhang *Department of Urology Surgery, The First Affiliation Hospital of China Medical University, Shenyang, 110000, Liaoning, China.
Jiyuan Hu *Department of Urology Surgery, The First Affiliation Hospital of China Medical University, Shenyang, 110000, Liaoning, China.
Haoyuan Zheng *Department of Urology Surgery, The First Affiliation Hospital of China Medical University, Shenyang, 110000, Liaoning, China.
Jiayi Ren *Institute of Women, Children and Reproductive Health, Shandong University, Jinan, 250012, Shandong, China.
Siyu Mu *Department of Neurology, The First Affiliation Hospital of China Medical University, Shenyang, 110000, Liaoning, China.
Yiming ChenDepartment of Urology Surgery, The First Affiliation Hospital of China Medical University, Shenyang, 110000, Liaoning, China.
Guoli SongState Key Laboratory of Robotics, Shenyang Institute of Automation, Chinese Academy of Sciences, Shenyang, 110016, China.
Ya-Ang ChenDepartment of Urology Surgery, The First Affiliation Hospital of China Medical University, Shenyang, 110000, Liaoning, China.
Gejun ZhangDepartment of Urology Surgery, The First Affiliation Hospital of China Medical University, Shenyang, 110000, Liaoning, China. 13897909605@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To evaluate the predictive utility of N6-methyladenosine (m6A)-associated long non-coding RNAs (lncRNAs) for the prognosis and immunotherapy response in papillary renal cell carcinoma (pRCC). Transcriptomic data of pRCC samples were extracted from the TCGA database. The m6A-related lncRNAs were identified by Pearson correlation analysis. Univariate and LASSO regression analyses were used to develop a risk model. The discrimination and predictive ability were evaluated through survival analysis, ROC analysis and consensus clustering. Tumor mutation burden (TMB) and immune infiltration of the risk groups were compared. A prognostic nomogram was constructed using six m6A-related lncRNAs, and validated through calibration and decision curve analysis (DCA). The lncRNAs HCG25 and NOP14-AS1 were knocked down in a human pRCC cell line using specific siRNA constructs, and the proliferation and migration rates were assessed by the CCK-8 and transwell assays. We identified a total of 153 m6A-related lncRNAs in pRCC datasets, of which six were selected for constructing a m6A-related lncRNA pRCC prognostic model. Mutations in the SETD2 gene correlated with worse prognosis. Significant differences were observed in immune cell infiltration between the two risk groups. A clinical prognostic nomogram for pRCC was further established based on clinical variables. In vitro assays further showed that HCG25 and NOP14-AS1 regulate the proliferation and migration of pRCC cells. The results validated the discrimination ability of both the m6A-related lncRNA pRCC prognostic model and the pRCC clinical prognostic nomogram. We developed a clinical prognostic nomogram for pRCC using pRCC prognostic-associated m6A-related lncRNAs, which can be utilized for predicting the prognosis and immune landscape of pRCC patients.

Indexed as

AdenosineCarcinoma, Renal CellKidney NeoplasmsNomogramsRNA, Long NoncodingBiomarkers, TumorCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMutationPrognosisAdenosineBiomarkers, TumorN-methyladenosineRNA, Long NoncodingImmune cell infiltrationLong non-coding RNA (lncRNA)M6A (N6-methyladenosine)Papillary renal cancer (pRCC)Prognostic modelTumor mutation burden (TMB)

Identifiers

PMID39732963
PMCPMC11682231

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.